36 terminated. 36 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 36 | Terminated 36 |
| Phase 2 | 6 | Terminated 6 |
Follow Adnexal Diseases: new trials by email Literature Review of Adnexal Diseases trials Research Report on Adnexal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) Upifitimab rilsodotin, Placebo - High Grade Serous Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Terminated | Mersana Therapeutics | 20 | 2022-06-23 | 2023-10-26 |
| Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin - Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Terminated | Mural Oncology, Inc | 456 | 2022-01-10 | 2025-08-28 |
| Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected Alpelisib, Olaparib, Paclitaxel - Ovarian Cancer | Phase 3 | Terminated | Novartis Pharmaceuticals | 358 | 2021-07-22 | 2026-10-19 |
| Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer Batiraxcept, Paclitaxel, Placebo - Platinum-resistant Ovarian Cancer | Phase 3 | Terminated | Aravive, Inc. | 366 | 2021-04-22 | 2023-10-30 |
| Contribution of Contrast Enhanced Ultrasound in the Diagnosis of Adnexal Torsion Contrast enhanced ultrasound - Adnexal Torsion | Phase 3 | Terminated | Central Hospital, Nancy, France | 11 | 2021-04-13 | 2026-04-08 |
| Efficacy of Letrozole in Recurrent Ovarian Cancer Letrozole 2.5mg, Standard single agent chemotherapy - Epithelial Ovarian Cancer | Phase 3 | Terminated | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 86 | 2020-06-22 | 2025-03-07 |
| Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer Exemestane, Placebo oral tablet - Ovarian Cancer | Phase 3 | Terminated | Ente Ospedaliero Ospedali Galliera | 23 | 2020-02-13 | 2024-02-12 |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer Carboplatin, Gemcitabine, Bevacizumab - Recurrent Ovarian Carcinoma | Phase 3 | Terminated | AGO Research GmbH | 9 | 2019-08-09 | 2022-02-24 |
| Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures Bupivacaine, Liposomal bupivacaine - Ovarian Cancer, Fibroids | Phase 3 | Terminated | University of California, Irvine | 13 | 2019-05-20 | 2024-08-23 |
| Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab - Ovarian Cancer | Phase 3 | Terminated | Pfizer | 79 | 2018-07-19 | 2023-04-06 |
| Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) carboplatin, paclitaxel, Avelumab - Ovarian Cancer | Phase 3 | Terminated | Pfizer | 998 | 2016-05-19 | 2020-07-14 |
| Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Veliparib, Paclitaxel, Carboplatin - Ovarian Cancer, Ovarian Neoplasm | Phase 3 | Terminated | AbbVie | 1140 | 2015-07-14 | 2024-10-26 |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients niraparib, Physician's choice - Neoplasms, Breast, Carcinoma of Breast | Phase 3 | Terminated | Tesaro, Inc. | 216 | 2014-02-25 | 2022-11-15 |
| A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy CAELYX, Topotecan HCl - Epithelial Ovarian Cancer | Phase 3 | Terminated | Xian-Janssen Pharmaceutical Ltd. | 32 | 2013-06-01 | 2015-12-23 |
| Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS Metformin, Dietary Restriction, Exercise Training - Polycystic Ovary Syndrome | Phase 3 | Terminated | Pennington Biomedical Research Center | 32 | 2012-05-01 | 2022-03-15 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer AMG 386, Paclitaxel, AMG 386 Placebo - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 1015 | 2012-01-01 | 2017-02-23 |
| Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) EC145, Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®), placebo - Ovarian Cancer | Phase 3 | Terminated | Endocyte | 441 | 2011-04-22 | 2021-09-30 |
| AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) AMG386 plus PLD, Placebo plus PLD - Fallopian Tube Cancer, Ovarian Cancer | Phase 3 | Terminated | Amgen | 223 | 2011-04-18 | 2017-12-02 |
| Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF) Dehydroepiandrosterone, Placebo - Premature Ovarian Failure | Phase 2 / Phase 3 | Terminated | David H. Barad | 5 | 2009-06-01 | 2012-09-10 |
Showing 20 of 36. Sign in to see all of them.
Ovarian Neoplasms (26) · Carcinoma, Ovarian Epithelial (10) · Fallopian Tube Neoplasms (6) · Breast Neoplasms (4) · Neoplasms (4) · Primary Ovarian Insufficiency (4) · Blast Crisis (2) · Burkitt Lymphoma (2) · Carcinoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Leukemia, Myeloid, Chronic-Phase (2) · Leukemia, Myelomonocytic, Chronic (2) · Leukemia, Neutrophilic, Chronic (2)
Endocrine System Diseases (36) · Female Urogenital Diseases (36) · Female Urogenital Diseases and Pregnancy Complications (36) · Genital Diseases (36) · Genital Diseases, Female (36) · Gonadal Disorders (36) · Ovarian Diseases (36) · Urogenital Diseases (36) · Neoplasms by Site (30) · Endocrine Gland Neoplasms (29) · Genital Neoplasms, Female (29) · Urogenital Neoplasms (29) · Neoplasms (28) · Neoplasms by Histologic Type (12)
Paclitaxel (11) · Carboplatin (9) · liposomal doxorubicin (7) · Gemcitabine (3) · Topotecan (3) · 1-dodecylpyridoxal (2) · Cisplatin (2) · Dehydroepiandrosterone (2) · Exercise (2) · trebananib (2) · Alpelisib (1) · Bevacizumab (1) · Bupivacaine (1) · Caloric Restriction (1) · Cyclophosphamide (1)
Amgen (2) · Pfizer (2) · AGO Research GmbH (1) · AGO Study Group (1) · AbbVie (1) · Aravive, Inc. (1) · Center for Human Reproduction (1) · Central Hospital, Nancy, France (1) · David H. Barad (1) · Endocyte (1) · Ente Ospedaliero Ospedali Galliera (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Gynecologic Oncology Group (1) · InterMune (1)
United States (25) · Italy (13) · Canada (11) · Belgium (10) · Germany (10) · United Kingdom (9) · Australia (8) · France (8) · South Korea (8) · Spain (8) · Poland (7) · Singapore (7) · Japan (6) · Taiwan (6) · Austria (5)
David Barad, MD, MS (2) · Norbert Gleicher, MD (2) · Andrea DeCensi (1) · Anna Pluzanska, MD (1) · Antonio Casado, MD (1) · Binh Nguyen, MD (1) · Bradley Monk, MD (1) · Christian Jackisch, MD, PhD (1) · Claudia Marchetti (1) · Eric Pujade-Lauraine, MD (1) · Felix Hilpert, MD, PhD (1)
PMID 37185961, PMID 37407274, PMID 19270260, PMID 20973267, PMID 23478059, PMID 24952307, PMID 28323951, PMID 28665051, PMID 30377436, PMID 31076365, PMID 33369580, PMID 34363762, PMID 34906376, PMID 36066851, PMID 37334673, PMID 40700681, PMID 40761032, PMID 41565553
2008 (1), 2009 (1), 2014 (1), 2015 (1), 2017 (1), 2018 (1), P30CA069533 (1), R00HD060762 (1), R01HD035629 (1)